Sign In
Buy BDSX
$16.10
+0.660 (+4.27%)
At Close: Jun 03, 2026
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
05:03pm, Thursday, 22'nd May 2025
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society
Biodesix to Participate in Upcoming Investor Conferences
06:00am, Wednesday, 21'st May 2025
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participat
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS
06:00am, Thursday, 15'th May 2025
LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Ph
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award
04:01pm, Wednesday, 14'th May 2025
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner.
Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript
08:22pm, Tuesday, 13'th May 2025
Biodesix, Inc. (NASDAQ:BDSX ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
06:15pm, Tuesday, 13'th May 2025
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Biodesix Announces First Quarter 2025 Results and Highlights
04:01pm, Tuesday, 13'th May 2025
Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025 ; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a r
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
06:00am, Tuesday, 29'th Apr 2025
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarte
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology Aggregate analysis
Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock?
01:06pm, Thursday, 06'th Mar 2025
Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript
08:06pm, Monday, 03'rd Mar 2025
Biodesix, Inc. (NASDAQ:BDSX ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowi
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
04:01pm, Monday, 03'rd Mar 2025
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Web
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
06:00am, Wednesday, 26'th Feb 2025
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief F
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
06:00am, Tuesday, 18'th Feb 2025
BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter a
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
06:00am, Friday, 10'th Jan 2025
Grew full-year revenue to an estimated $71.3 million, an increase of 45% Grew full-year revenue to an estimated $71.3 million, an increase of 45%
